Literature DB >> 2959183

Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension.

S Adnot1, P E Chabrier, P Andrivet, I Viossat, J Piquet, C Brun-Buisson, Y Gutkowska, P Braquet.   

Abstract

To define the relationship between plasma levels of immunoreactive atrial natriuretic peptide (IR-ANP) and hemodynamic parameters in patients with chronic pulmonary artery hypertension, we measured plasma concentrations of the peptide in 15 patients during right heart catheterization. Eleven patients had chronic obstructive pulmonary disease and 4 had pulmonary vascular disease of diverse etiology. At rest, plasma concentrations of IR-ANP positively correlated with mean pulmonary artery pressure (r = 0.70, p less than 0.01) and pulmonary vascular resistance (r = 0.88, p less than 0.001), but not with right atrial pressure. Nine of these patients, all with chronic obstructive pulmonary disease, were also evaluated during exercise. Plasma concentrations of IR-ANP increased from 131 +/- 22 to 191 +/- 30 pg/ml (p less than 0.003) at maximal exercise, whereas pulmonary artery pressure increased from 29 +/- 1.5 to 56 +/- 2.5 mm Hg and right atrial pressure from 5 +/- 1 to 13 +/- 2 mm Hg. Increases of plasma IR-ANP concentrations correlated with changes in pulmonary artery pressure and right atrial pressure but not with changes in pulmonary capillary wedge pressure. These findings suggest that ANP is released in response to an increase in pulmonary artery pressure and are consistent with the hypothesis that ANP could modulate the pulmonary vascular tone in patients with pulmonary artery hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959183     DOI: 10.1164/ajrccm/136.4.951

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Effects of urapidil on blood pressure and volume regulatory hormones during exercise in normal subjects.

Authors:  S Adnot; F Lotte; G Atlan
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis.

Authors:  B J Freund; C E Wade; J R Claybaugh
Journal:  Sports Med       Date:  1988-12       Impact factor: 11.136

3.  Urinary cGMP concentrations in severe primary pulmonary hypertension.

Authors:  M Bogdan; M Humbert; J Francoual; C Claise; P Duroux; G Simonneau; A Lindenbaum
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

4.  Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.

Authors:  H Jin; R H Yang; Y F Chen; R M Jackson; S Oparil
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Effects of atrial natriuretic peptide and nitroprusside on isolated pulmonary resistance and conduit arteries from rats with pulmonary hypertension.

Authors:  J C Wanstall; J S Thompson; A H Morice
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

Authors:  T K Rogers; W Sheedy; J Waterhouse; P Howard; A H Morice
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

7.  Atrial natriuretic peptide in stable and decompensated chronic obstructive pulmonary disease.

Authors:  K Skwarski; M Lee; L Turnbull; W MacNee
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

Review 8.  Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?

Authors:  Robert W Schrier; Shweta Bansal
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-09       Impact factor: 8.237

9.  Atrial natriuretic peptide concentrations in children with pulmonary hypertension: correlation with hemodynamic measurements.

Authors:  F S Tunaoglu; F R Olgunturk; N Gokcora; C Turkyilmaz; F Gurbuz
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

10.  Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

Authors:  S Adnot; P Andrivet; P E Chabrier; J Piquet; P Plas; P Braquet; F Roudot-Thoraval; C Brun-Buisson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.